Suppr超能文献

核基质蛋白、纤连蛋白、膀胱癌抗原及晨尿细胞学检查在膀胱肿瘤检测中的比较评估

Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.

作者信息

Eissa Sanaa, Swellam Menha, Sadek M, Mourad M Sherif, El Ahmady O, Khalifa A

机构信息

Oncology Diagnostic Unit, Biochemistry Department, Faculty of Medicine, Ain Shams University, Cairo, Eygpt.

出版信息

J Urol. 2002 Aug;168(2):465-9.

Abstract

PURPOSE

We evaluate the diagnostic efficacy of nuclear matrix protein-22 (NMP22, Matritech, Newton, Massachusetts), fibronectin and urinary bladder cancer antigen (UBC, IDL Biotech, Borlange, Sweden) compared with voided urine cytology in the detection of bladder cancer.

MATERIALS AND METHODS

A total of 168 patients provided a single voided urine sample for NMP22, fibronectin an ideal monoclonal for urinary bladder cancer and cytology before cystoscopy. Cystoscopy was done for all patients as the reference standard for identification of bladder cancer. Biopsy of any suspicious lesion was performed for histopathological examination. Of the 168 cases 100 were histologically diagnosed as bladder cancer, whereas the remaining 68 had benign urological disorders. A group of 47 healthy volunteers were also enrolled in this study. Voided urine was evaluated by NMP22, fibronectin and UBC, and their values were expressed relative to mg. creatinine.

RESULTS

The optimal threshold values for NMP22, fibronectin and UBC were calculated by receiver operator characteristics curves as 27 units per mg. creatinine, 198 mg./mg. creatinine and 13 ng./mg. creatinine, respectively. The levels and positive rates of the 3 parameters were significantly higher in the malignant group compared to either the benign group or normal controls. Of the entire group NMP22, fibronectin and UBC were positive in 93.2%, 91% and 68.2%, respectively in bladder cancer cases with positive cytology. Moreover, these positive rates were significantly higher in bilharzial bladder cancer cases (58.8%, 67.5%, 58.8%, respectively) compared to nonbilharzial cases (35.6%, 36.3%, 31.1%). Overall sensitivity and specificity were 85% and 91.3% for NMP22, 83% and 82.6% for fibronectin, 67% and 80.8% for UBC and 44% and 100% for voided urine cytology. Combined sensitivity of voided urine cytology with the 3 biomarkers together was higher than either combined sensitivity of voided urine cytology with 1 of the biomarkers or than that of the biomarker alone.

CONCLUSIONS

Our data indicate that NMP22 and fibronectin had superior sensitivities compared to UBC and voided urine cytology, while NMP22 and voided urine cytology had the highest specificities. The combined use of markers increased the sensitivity of cytology from 44% to 95.3%. The higher sensitivities of markers in bilharzial than nonbilharzial bladder cancer highlight their clinical use in screening patients with urinary bilharziasis.

摘要

目的

我们评估核基质蛋白-22(NMP22,马萨诸塞州牛顿市的Matritech公司)、纤连蛋白和膀胱癌抗原(UBC,瑞典博伦厄的IDL生物技术公司)与晨尿细胞学检查相比在膀胱癌检测中的诊断效能。

材料与方法

共有168例患者在膀胱镜检查前提供了一份晨尿样本用于检测NMP22、纤连蛋白(一种理想的膀胱癌单克隆抗体)和进行细胞学检查。对所有患者均进行膀胱镜检查,将其作为识别膀胱癌的参考标准。对任何可疑病变进行活检以进行组织病理学检查。在这168例病例中,100例经组织学诊断为膀胱癌,其余68例患有良性泌尿系统疾病。另外招募了47名健康志愿者参与本研究。通过NMP22、纤连蛋白和UBC对晨尿进行评估,其值以相对于毫克肌酐表示。

结果

通过受试者工作特征曲线计算得出NMP22、纤连蛋白和UBC的最佳阈值分别为每毫克肌酐27单位、每毫克肌酐198毫克和每毫克肌酐13纳克。与良性组或正常对照组相比,恶性组中这3项参数的水平和阳性率显著更高。在整个研究组中,细胞学检查呈阳性的膀胱癌病例中,NMP22、纤连蛋白和UBC的阳性率分别为93.2%、91%和68.2%。此外,与非血吸虫性膀胱癌病例(分别为35.6%、36.3%、31.1%)相比,血吸虫性膀胱癌病例中这些阳性率显著更高(分别为58.8%、67.5%、58.8%)。NMP22的总体敏感性和特异性分别为85%和91.3%,纤连蛋白为83%和82.6%,UBC为67%和80.8%,晨尿细胞学检查为44%和100%。晨尿细胞学检查与这3种生物标志物联合使用时的敏感性高于晨尿细胞学检查与其中1种生物标志物联合使用时的敏感性,也高于单独使用生物标志物时的敏感性。

结论

我们的数据表明,与UBC和晨尿细胞学检查相比,NMP22和纤连蛋白具有更高的敏感性,而NMP22和晨尿细胞学检查具有最高的特异性。标志物联合使用将细胞学检查的敏感性从44%提高到了95.3%。与非血吸虫性膀胱癌相比,血吸虫性膀胱癌中标志物的更高敏感性凸显了它们在筛查埃及血吸虫病患者中的临床应用价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验